Clinical Trials Logo

Clinical Trial Summary

Background:

- Obsessive-compulsive disorder (OCD) is a common childhood disorder that often does not respond to standard treatments. Researchers are exploring the role that a brain chemical called glutamate plays in symptoms of OCD, and are testing a drug called riluzole that reduces glutamate to see if changing the levels of glutamate in the brain will help treat the disorder.

- Researchers are interested in using magnetic resonance spectroscopy (MRS), a type of magnetic imaging, to take pictures of various chemicals in the brain. MRS images will be used to detect changes in brain levels of glutamate in children taking riluzole.

Objectives:

- To use magnetic resonance spectroscopy to study the levels of glutamate in the brains of children and adolescents who have been taking riluzole.

Eligibility:

- Children and adolescents ages 7 to 17 who are enrolled in the current NIMH riluzole trial protocol (05-M-0225), who are able to lie still in the scanner for about an hour each time, and who are willing to have up to three MRS scans.

Design:

- Researchers will study some children/adolescents before they begin to take the study medication riluzole or placebo these children will have an MRS scan before starting the study medication. The scan will take about an hour.

- About 2 weeks after reaching the full dose on the study medication, participants will have a second hour-long MRS scan. Participants will have a third MRS scan after being on the study medication for 12 weeks.

- Some children who have already completed 12 weeks on riluzole or placebo, and are now taking riluzole, will have only one MRS scan.


Clinical Trial Description

Objective

This study uses magnetic resonance spectroscopy (MRS) to measure the neurotransmitter glutamate in the anterior cingulate cortex (and, if tolerated, the left caudate nucleus and possibly the thalamus) in children and adolescents.

Study Population

All of the subjects will be participants in an ongoing double-blind placebo-controlled trial (05-M-0225) of a glutamate antagonist, the drug riluzole, for Obsessive-Compulsive Disorder (OCD). The subjects are male and female children and adolescents, ages 7-17 years. They will all have met criteria for clinically significant OCD and will have failed to benefit from standard-of-care treatments or have been unable to tolerate the treatments. Some of the subjects will also have a diagnosis on the autism spectrum.

Design

In one group of sixteen young people, glutamate will be measured in the anterior cingulate cortex at three points in time:

- at baseline, before starting riluzole or placebo;

- within ten to fourteen days of the baseline evaluation, after reaching full dose of the study drug (active drug or placebo) to which the sixteen subjects have just been randomized;

- at the end of the twelve weeks of the double-blind phase of the study.

In a second group of sixteen young people, all of whom are subjects in the open-label phase of the same study, glutamate will be measured (first) in the anterior cingulate cortex at a single point in time when each subject has achieved steady state on the open-label drug riluzole. If the subject tolerates additional time in the scanner, glutamate will also be measured in the left caudate and possibly in the left thalamus. Glutamate levels in this group will be correlated with change in OCD measures.

Outcome Measures

- In the first group, change in glutamate activity in anterior cingulate associated with active drug (riluzole) administration, as compared with change in glutamate activity for the subjects taking placebo.

- In the second group, correlation between serum riluzole level, glutamate activity (or flux) in anterior cingulate (and possibly in the caudate and thalamus), and therapeutic effect. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01019967
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase N/A
Start date November 17, 2009
Completion date September 20, 2012

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02625116 - ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders
Not yet recruiting NCT06381856 - Improving Participation of Autistic Children and Adolescents in the Habilitation Process
Recruiting NCT02280746 - Gluten for Autism Spectrum Disorders N/A
Completed NCT01945957 - Brain Imaging of Intranasal Oxytocin Treatment in Autism Phase 1
Completed NCT01661855 - A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD Phase 2
Completed NCT01691066 - Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder N/A
Completed NCT01780090 - Handheld Technology for Speech Development in Students With Autism N/A
Completed NCT01694667 - Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Phase 2
Completed NCT01592747 - Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine Phase 2
Active, not recruiting NCT01417026 - Intranasal Oxytocin and Learning in Autism Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT01695200 - Omega-3 Fatty Acids in Autism Spectrum Disorders Phase 4
Completed NCT02300597 - Internet-based Support for Young People With ADHD and Autism - a Controlled Study N/A
Not yet recruiting NCT00695812 - The Development of Younger Siblings of Children With Autism Now at 10 Years of Age N/A
Completed NCT01675414 - Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD) N/A
Recruiting NCT05910502 - Project AFECT (Autism Family Empowerment Coaching and Training Program) N/A
Completed NCT02081027 - Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders Early Phase 1
Completed NCT02797379 - The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders N/A
Terminated NCT01730079 - Near Infrared Spectroscopy in Children With Autism and ADHD
Completed NCT01603225 - Transcranial Direct Current Stimulation and Autism